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Objectives The aims of this study were to assess the prognostic value of cardiac troponin I levels, measured with a new
high-sensitivity assay, in low-risk patients with stable coronary artery disease (CAD) and to contrast its determi-
nants and prognostic merit with that of high-sensitivity cardiac troponin T (hs-TnT).
Background New, highly sensitive cardiac troponin assays permit evaluation of the association between troponin levels and
outcomes in patients with stable CAD.
Methods High-sensitivity cardiac troponin I (hs-TnI) levels at baseline were assessed in 3,623 patients with stable CAD
and preserved systolic function enrolled in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme
Inhibitor Therapy) trial.
Results In total, 98.5% of patients had hs-TnI concentrations higher than the detection level (1.2 pg/ml). hs-TnI corre-
lated moderately with hs-TnT (r  0.44) and N-terminal pro–B-type natriuretic peptide (r  0.39) but only weakly
with age (r  0.17) and estimated glomerular filtration rate (r  0.11). During a median follow-up period of
5.2 years, 203 patients died of cardiovascular causes or were hospitalized for heart failure, and 209 patients
had nonfatal myocardial infarctions. In analyses adjusting for conventional risk markers, N-terminal pro–B-type
natriuretic peptide, and hs-TnT, hs-TnI levels in the fourth compared with the 3 lower quartiles were associated
with the incidence of cardiovascular death or heart failure (hazard ratio: 1.88; 95% confidence interval: 1.33 to
2.66; p  0.001). There was a significant, albeit weaker association with nonfatal myocardial infarction (hazard
ratio: 1.44; 95% confidence interval: 1.03 to 2.01; p  0.031). In the same models, hs-TnT concentrations were
associated with the incidence of cardiovascular death or heart failure but not of myocardial infarction.
Conclusions In patients with stable CAD, hs-TnI concentrations are associated with cardiovascular risk independently of con-
ventional risk markers and hs-TnT. (Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy
[PEACE]; NCT00000558) (J Am Coll Cardiol 2013;61:1240–9) © 2013 by the American College of Cardiology
Foundation
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March 26, 2013:1240–9 Troponin I in Stable CADIn patients with acute chest pain, measurement of cardiac
troponin I (cTnI) or cardiac troponin T (cTnT) is routinely
used to diagnose acute myocardial infarction (AMI) (1). In
he setting of acute coronary syndromes, troponin elevation
lso provides information concerning the risk for subsequent
dverse cardiovascular events, as well as the benefit of
herapeutic intervention (2). The introduction of high-
ensitivity assays permits the accurate determination of very
ow levels of circulating cardiac troponins (3). Using a
ighly sensitive assay for cTnT, we recently demonstrated
he presence of detectable levels in a large proportion of
atients with stable coronary artery disease (CAD) (4).
oreover, cTnT concentrations were independently as-
ociated with the incidence of cardiovascular death and
eart failure in these patients.
Although conventional cTnT and cTnI assays have been
ommonly considered to provide comparable diagnostic
nformation in acute coronary syndromes (5), recent studies
omparing the diagnostic value of highly sensitive assays for
TnT and cTnI have revealed interesting differences with
otential clinical implications (6). Moreover, acute ischemia
ay have differential effects on cTnT (7) and cTnI (8)
elease. Recent data from asymptomatic subjects at high risk
or atherosclerotic events suggest that cTnI provides inde-
endent information concerning the risk for future AMI
9), whereas in another study, the association between cTnT
nd the risk for AMI in patients with stable CAD was weak
nd not significant after adjustment for confounders (4).
aken together, these observations suggest that factors
nfluencing low-level, chronic troponin elevation may differ
etween cTnT and cTnI. Whether the potential differences
n chronic release and degradation patterns have prognostic
onsequences is unknown. Moreover, whether cTnI pro-
ides complementary prognostic information to cTnT in
atients with stable CAD has not been evaluated.
Accordingly, the objectives of the present study of a large
ohort of patients with stable CAD and preserved left
entricular (LV) ejection fractions were first to assess the
eterminants and prognostic value of circulating cTnI
easured using a prototype high-sensitivity assay and sec-
nd to contrast the results with those obtained using a
igh-sensitivity assay for cTnT.
ethods
tudy design and patients. This is a biomarker substudy of
he PEACE (Prevention of Events With Angiotensin-
onverting Enzyme Inhibitor Therapy) trial. The design,
from Abbott Diagnostics and Roche Diagnostics. Dr. Sabatine has received research
grant support from Abbott Laboratories, BRAHMS, Critical Diagnostics, and Roche
Diagnostics through Brigham and Women’s Hospital. Dr. Braunwald has received
grant support from Knoll Pharmaceuticals and Abbott Laboratories (as a supplement
to the PEACE trial). All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.c
Manuscript received September 18, 2012; revised manuscript received November
22, 2012, accepted December 10, 2012.ntry criteria, and main results of
his trial have been described pre-
iously (10). In summary, from
ovember 1996 to June 2000,
,290 patients were randomized to
eceive either the angiotensin-
onverting enzyme inhibitor tran-
olapril or placebo. Entry criteria
ere age 50 years, documented
AD, and LV ejection fraction
40%; qualitatively normal results
n left ventriculography; or the
bsence of LV wall motion abnor-
alities on echocardiography.
one of the patients had been
ospitalized with unstable angina
uring the preceding 3 months.
ll patients included were deemed
o be free of heart failure at the
ime of randomization. All pa-
ients who had baseline ethyl-
nediamine-tetraacetic acid plasma
amples available for measurement
f high-sensitivity cTnT (hs-TnT) and serum samples available
or determination of high-sensitivity cTnI (hs-TnI) (n  3,623)
ere included in the present substudy. The institutional review
oards of the participating sites reviewed and approved the
tudy, and all participants provided written informed consent.
On the basis of prior data concerning the prognostic value
f hs-TnT in patients with stable CAD, the primary
utcomes examined in the present analysis were 1) a
omposite of cardiovascular death and nonfatal heart failure
nd 2) nonfatal AMI (4). Cardiovascular death and nonfatal
MI were pre-specified endpoints of the PEACE trial. To
scertain these endpoints, medical records were reviewed
y a central, blinded morbidity and mortality committee.
eart failure was classified by local staff members and
onfirmed by the coordinating center through review of
edical records and required hospitalization with heart
ailure as the primary diagnosis. Clinical events were all
lassified before biomarker measurement.
lood sampling procedures and biochemical assays.
amples of venous blood were obtained before randomization.
he test tube was centrifuged at room temperature, and serum
nd plasma were aspirated and frozen at 20°C at individual
enters. Within 3 months of collection, serum and plasma
amples were shipped on dry ice to the central laboratory for
torage at 70°C or colder, pending analysis. For hs-TnI and
s-TnT analysis, samples were shipped on dry ice to Akershus
niversity Hospital (Lørenskog, Norway).
hs-TnI in serum was determined using a prototype cTnI assay
rom Abbott Diagnostics (Lake Forest, Illinois): ARCHITECT
TAT High Sensitive Troponin. The level of detection for this
ssay has been reported to be 1.2 pg/ml (range: 0 to 50,000
g/ml), with a coefficient of variation of 10% observed at a
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CI  confidence interval
CRP  C-reactive protein
cTnI  cardiac troponin I
cTnT  cardiac troponin T
GFR  glomerular filtration
rate
HR  hazard ratio
hs-TnI  high-sensitivity
cardiac troponin I
hs-TnT  high-sensitivity
cardiac troponin T
LV  left ventricular
NT-proBNP  N-terminal
pro–B-type natriuretic
peptideoncentration of 3.0 pg/ml, and the diagnostic cutoff repre-
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Troponin I in Stable CAD March 26, 2013:1240–9senting the 99th percentile in the general population is 15.6
pg/ml in women and 34.2 pg/ml in men (3). Levels lower than
the detection limit were assigned a value of 1.2 pg/ml.
hs-TnT, N-terminal pro–B-type natriuretic peptide
(NT-proBNP), and C-reactive protein (CRP) concentra-
tions in plasma were determined as described previously
(4,11). Glomerular filtration rate (GFR) was estimated
using the 4-variable Modification of Diet in Renal Disease
equation (12). All biochemical testing was performed by
experienced laboratory personnel blinded to clinical out-
comes and treatment allocation.
Statistical analysis. Sex-specific quartiles of hs-TnI were
alculated. Highly skewed variables (hs-TnI, hs-TnT, CRP,
nd NT-proBNP) were successfully logarithmically trans-
ormed to normalize the distribution. Comparisons of
aseline characteristics across the different sex-specific quar-
iles of hs-TnI were done using the test for trend for
ontinuous variables and the Cochran-Armitage test for
ategorical variables. For continuous variables, each case was
ssigned a rank, and the median value within each quartile
nd the correlation between this value and the category
umber were calculated. Pearson’s correlations were used to
est the relationships between continuous variables. Deter-
inants of hs-TnI and hs-TnT levels were further exam-
ned by generating multivariate linear regression models.
ariables identified in univariate analyses with p 0.20
ere entered into the multivariate model, which was further
educed by the F-ratio test. Cox proportional hazards
egression models were estimated to test the relationships
etween hs-TnI and the composite outcome of cardiovas-
ular death or nonfatal heart failure and between hs-TnI
nd nonfatal AMI. Patients were censored at their last visits.
ox models for hs-TnI were initially adjusted for treatment
ssignment and baseline variables known to be important
redictors of cardiovascular events: age, sex, body mass
ndex, ejection fraction 50%, estimated GFR, current
moking, history of hypertension, history of diabetes, his-
ory of AMI, history of percutaneous coronary intervention,
istory of coronary artery bypass grafting, history of stroke,
istory of transient ischemic attack, history of intermittent
laudication, serum total cholesterol, high-sensitivity CRP,
se of a beta-blocker, use of a lipid-lowering drug, use of
spirin or an antiplatelet medication, and use of a diuretic
edication. Models were reduced using the stepwise selec-
ion method with the Akaike information criterion applied
t each step (13). Estimates of the C-index for the Cox
egression models were calculated according to the method
f Pencina and D’Agostino (14). The discriminative value
as examined using the integrated discrimination improve-
ent measure, estimating the change in the predicted
urvival probabilities after the inclusion of hs-TnI or hs-
nT to the models in patients with and without events (15).
umulative incidence plots categorized according to the
ex-specific quartiles of hs-TnI were generated. A p value
0.05 was considered to be statistically significant, and allests were 2 sided. SAS version 9.2 (SAS Institute Inc., iary, North Carolina), SPSS version 16.0 (SPSS, Inc.,
hicago, Illinois), and Stata version 11.0 (StataCorp LP,
ollege Station, Texas) were used for analyses.
esults
istribution and determinants of hs-TnI. Concentrations of
s-TnI at or above the limit of detection of the assay (1.2
g/ml) were observed in 3,567 patients (98.5%), whereas
oncentrations of hs-TnI at or above the sex-specific 99th
ercentile of a general population (15.6 pg/ml in women
nd 34.2 pg/ml in men) were evident in 105 patients (2.9%).
n comparison, concentrations of hs-TnT at or above the
ex-specific 99th percentile of a general population (14.2
g/ml in men and 10.0 pg/ml in women) were evident in
95 of 3,679 patients (10.9%). The distribution patterns of
s-TnI and hs-TnT are depicted in Figure 1.
Characteristics of the patients according to the sex-
pecific quartiles of hs-TnI concentrations at baseline are
hown in Table 1. Increasing quartiles of hs-TnI were
ssociated with a number of conventional risk markers. By
earson’s correlation, logarithmically transformed hs-TnI
evels were correlated moderately with hs-TnT (r  0.44)
nd NT-proBNP (r  0.39) but only weakly with age (r 
.17) and estimated GFR (r  0.11). In contrast, the
ssociations of hs-TnT with age (r  0.33) and estimated
FR (r  0.16) were somewhat more robust.
To assess the relative contribution of potential determi-
ants of troponin levels, separate series of linear regression
nalyses were conducted with logarithmically transformed
s-TnI and hs-TnT concentrations as the dependent vari-
bles, respectively. By univariate linear regression analyses, a
umber of conventional risk markers and risk factors were
ssociated with higher logarithmically transformed concen-
rations of both hs-TnI and hs-TnT (Table 2). However,
he strength of associations differed somewhat between
s-TnI and hs-TnT for several variables. For instance, a
istory of AMI was significantly associated with hs-TnI
p  0.001) but not hs-TnT (p  0.78), whereas current
moking was inversely related to hs-TnT (p  0.001) but
ot to hs-TnI (p  0.07). Moreover, by multivariate linear
egression analysis, history of AMI was identified as inde-
endently associated with hs-TnI but not hs-TnT. Con-
ersely, the association with eGFR was significant for
s-TnT (p  0.001) but not for hs-TnI (p  0.12). The
ssociations with age and sex also appeared to be somewhat
tronger for hs-TnT than for hs-TnI (Table 2).
s-TnI and the incidence of cardiovascular death or
onfatal heart failure. During a median follow-up period
f 5.2 years, there were 203 (5.6%) cardiovascular deaths or
rst hospitalizations for heart failure. The association be-
ween hs-TnI levels by quartiles and the cumulative inci-
ence of cardiovascular death or heart failure is displayed in
igure 2. By univariate analysis, there was a strong and
raded association between hs-TnI levels at baseline and the
ncidence of cardiovascular death or heart failure (hazard
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March 26, 2013:1240–9 Troponin I in Stable CADratio [HR] per 1-SD increase in the natural logarithm of
hs-TnI: 1.68; 95% confidence interval [CI]: 1.54 to 1.84];
p  0.0001). In the final multivariate model that adjusted
for age, ejection fraction 50%, estimated GFR, current
smoking, serum cholesterol, prior hypertension, diabetes,
AMI, coronary artery bypass grafting, arterial claudication,
and use of lipid-lowering drugs, as well as for CRP and
NT-proBNP, the association remained strong and highly
significant (HR: 1.34; 95% CI: 1.19 to 1.51; p  0.0001).
When considering cardiovascular death and nonfatal heart
failure as separate endpoints, similar relationships were ob-
served. Thus, the crude and adjusted HRs for the association
between hs-TnI as a log-transformed continuous variable and
cardiovascular death were 1.60 (95% CI: 1.42 to 1.81; p 
0.0001) and 1.30 (95% CI: 1.10 to 1.52; p  0.002), respec-
tively. Corresponding HRs for the endpoint of nonfatal heart
failure were 1.86 (95% CI: 1.64 to 2.11; p 0.0001) and 1.42
95% CI: 1.20 to 1.69; p  0.0001).
The association between increasing quartiles of hs-TnI
nd hs-TnT and the incidence of cardiovascular death or
eart failure suggested threshold effects corresponding to
he 75th percentile (Fig. 2). Dichotomizing patients accord-
ng to this hs-TnI level, the crude HR for patients in the
ourth quartile compared with the 3 lower quartiles was 4.18
95% CI: 3.15 to 5.54; p  0.0001). The association
emained highly significant after multivariate adjustment
HR: 2.12; 95% CI: 1.54 to 2.93; p  0.0001). Similar
esults were obtained when considering cardiovascular death
nd nonfatal heart failure as individual endpoints. Thus, the
djusted HRs were 2.01 (95% CI: 1.33 to 3.05; p  0.001)
or cardiovascular death and 2.14 (95% CI: 1.32 to 3.49;
Figure 1 Distribution Patterns of hs-TnI and hs-TnT in Stable C
The patterns of distribution of high-sensitivity cardiac troponin I (hs-TnI) and high-s
ease (CAD) differed slightly. Concentrations of hs-TnI at or above the limit of detec
portion of patients had concentrations of hs-TnI at or above the sex-specific 99th
sex-specific 99th-percentile values of a general population are 15.6 pg/ml in wom
men for hs-TnT. 0.002) for nonfatal heart failure. ps-TnI and the incidence of nonfatal myocardial infarction.
uring follow-up, there were 209 hospitalizations for non-
atal AMI. By univariate analysis, the association between
ogarithmically transformed hs-TnI levels and AMI was less
trong than the association with cardiovascular death or
eart failure but still highly significant (HR: 1.30; 95% CI:
.15 to 1.47; p  0.0001). In the final multivariate model
hat adjusted for age, ejection fraction 50%, current
moking, prior hypertension, diabetes, and coronary ar-
ery bypass grafting, as well as for CRP and NT-proBNP,
he association remained significant (HR: 1.20; 95% CI:
.04 to 1.37; p  0.010). Further adjustment for history
f AMI did not alter the results. Dichotomizing patients
ccording to the 75th percentile resulted in an unadjusted
R of 1.75 (95% CI: 1.31 to 2.35); after multivariate
djustment, the HR was 1.41 (95% CI: 1.03 to 1.94; p 
.034).
ifferential prognostic value of hs-TnI and hs-TnT.
orcing both hs-TnI and hs-TnT into the full multivariate
odels demonstrated that both variables, entered as continu-
us or as dichotomous variables (at the 75th-percentile cut
oints), provided strong and independent prognostic informa-
ion for the combined endpoint of cardiovascular death and
onfatal congestive heart failure (Table 3). For the endpoint of
onfatal AMI, the association was highly significant for hs-
nI but not for hs-TnT (Table 4).
After dichotomizing patients according to the sex-
pecific 99th-percentile values of a healthy reference popu-
ation for hs-TnI (34.2 pg/ml in men and 15.6 pg/ml in
omen), the association remained highly significant after
ultivariate adjustment (HR: 1.96; 95% CI: 1.40 to 2.74;
ity cardiac troponin T (hs-TnT) in 3,623 patients with stable coronary artery dis-
f the assay (1.2 pg/ml) were observed in 3,567 patients (98.5%). A lower pro-
tile of a general population (2.9%) than was observed for hs-TnT (10.9%). The
34.2 pg/ml in men for hs-TnI and 10.0 pg/ml in women and 14.2 pg/ml inAD
ensitiv
tion o
percen
en and 0.0001). Using the sex-specific 99th-percentile values
Patient Characteristics by Quartile of hs-TnITable 1 Patient Characteristics by Quartile of hs-TnI
Variable
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Total No.
of Patients Value
Total No.
of Patients Value
Total No.
of Patients Value
Total No.
of Patients Value
p Value
for Trend
hs-TnI (pg/ml)
Men 743 1.2–3.0 748 3.1–4.5 710 4.6–7.3 732 7.4–610.1
Women 180 1.2–2.5 166 2.6–3.9 176 4.0–6.3 168 6.4–577.17
Demographic characteristics
Age (yrs) 923 61.7 7.4 914 63.9 7.9 886 65.0 8.3 900 66.0 8.4 0.001
Women 923 180 (19.5%) 914 166 (18.2%) 886 176 (19.9%) 900 168 (18.7%)
Body mass index (kg/m2) 917 28.1 4.5 910 28.3 4.4 878 28.7 5.0 899 29.0 4.9 0.001
Medical history
Documented myocardial infarction 923 425 (46.0%) 914 509 (55.7%) 885 560 (63.3%) 900 554 (61.6%) 0.001
Angina pectoris 923 694 (75.2%) 914 663 (72.5%) 885 639 (72.2%) 900 645 (71.7%) 0.255
Percutaneous coronary intervention 922 464 (50.3%) 914 429 (46.9%) 885 420 (47.5%) 900 343 (38.1%) 0.072
Coronary artery bypass grafting 923 256 (27.7%) 914 286 (31.3%) 885 341 (38.5%) 900 394 (43.8%) 0.001
Diabetes mellitus 923 135 (14.6%) 914 127 (13.9%) 885 142 (16.0%) 900 179 (19.9%) 0.037
Previous hypertension 923 325 (35.2%) 914 373 (40.8%) 885 425 (48.0%) 900 479 (53.2%) 0.001
Intermittent claudication 923 63 (6.8%) 914 70 (7.7%) 885 91 (10.3%) 900 95 (10.6%) 0.049
TIA 923 25 (2.7%) 914 32 (3.5%) 885 24 (2.7%) 900 36 (4.0%) 0.224
Stroke 923 25 (2.7%) 914 36 (3.9%) 885 44 (5.0%) 899 50 (5.6%) 0.049
Current smokers 923 143 (15.5%) 913 145 (15.9%) 884 130 (14.7%) 900 125 (13.9%) 0.345
Mean blood pressure (mm Hg)
Systolic 921 129.7 15.2 914 131.5 16.3 885 135.3 17.0 900 137.2 17.5 0.001
Diastolic 921 77.8 9.7 914 77.6 10.0 885 78.6 9.8 900 78.6 10.2 0.001
Laboratory determinations
LVEF 50% 827 154 (17.4%) 891 195 (21.9%) 866 246 (28.4%) 883 277 (31.4%) 0.001
eGFR (ml/min/1.73 m2) 922 81.9 19.8 914 78.1 17.7 883 77.0 19.3 897 75.1 19.8 0.001
Serum cholesterol (mg/dl) 897 190.4 39.3 875 193.0 38.3 844 190.6 38.5 862 193.9 38.9 0.001
CRP (mg/l) 917 1.5 (1.4–1.6) 907 1.7 (1.5–1.8) 878 1.8 (1.7–1.9) 892 2.1 (1.9–2.2) 0.001
NT-proBNP (pg/ml) 917 84.5 (80.1–89.1) 903 114.9 (108.5–121.7) 876 169.2 (159.2–179.9) 890 254.4 (237.9–272.1) 0.001
hs-TnT (pg/ml) 904 4.9 4.1 879 5.8 4.7 857 7.8 4.7 873 11.7 8.7 0.001
Medications
Assignment to trandolapril 923 453 (49.1%) 914 468 (51.2%) 886 440 (49.7%) 900 449 (49.9%) 0.474
Calcium-channel blockers 923 304 (32.9%) 914 312 (34.1%) 885 290 (32.8%) 899 298 (33.1%) 0.489
Beta-blockers 923 567 (61.4%) 914 579 (63.3%) 885 544 (61.5%) 899 555 (61.7%) 0.485
Aspirin or other antiplatelet medications 923 855 (92.6%) 914 844 (92.3%) 885 810 (91.5%) 899 799 (88.9%) 0.129
Lipid-lowering drugs 923 712 (77.1%) 914 649 (71.0%) 885 635 (71.8%) 898 603 (67.1%) 0.050
Values are range, mean  SD, n (%) or geometric means (95% confidence intervals).
CRP C-reactive protein; hs-TnT high-sensitivity cardiac troponin T; eGFR estimated glomerular filtration rate; hs-TnI high-sensitivity cardiac troponin I; LVEF left ventricular ejection fraction; NT-proBNP N-terminal pro–B-type natriuretic peptide; TIA transient
ischemic attack.
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March 26, 2013:1240–9 Troponin I in Stable CADof a healthy reference population for hs-TnT (14.2 pg/ml in
men and 10.0 pg/ml in women), the association was
attenuated and borderline significant (HR: 1.43; 95% CI:
1.00 to 2.05; p  0.051) (Table 5).
To assess whether the combined use of hs-TnT and
hs-TnI permitted the identification of patients at particu-
larly high risk, we estimated the HR for cardiovascular
death or heart failure and for AMI in patients who had
hs-TnI and hs-TnT concentrations greater than or equal to
the sex-specific 75th percentile of healthy subjects (hs-TnI:
4.2 pg/ml in men, 2.8 pg/ml in women; hs-TnT: 5.6 pg/ml
in men, 3.9 pg/ml in women) using patients who had
concentrations of both hs-TnI and hs-TnT lower than the
sex-specific 75th percentile of healthy subjects as the refer-
ence (Table 6). In addition, we estimated the HR of subjects
with discordant values (i.e., those with concentrations
greater than or equal to the sex-specific 75th percentile of
healthy subject with 1 assay only) (Table 6). High levels of
both hs-TnI and hs-TnT were associated with substantially
increased risk for cardiovascular death or heart failure (HR:
7.57; 95% CI: 4.30 to 13.35), whereas the risk associated
with high levels of either hs-TnI or hs-TnT was more
moderate (HR: 2.25; 95% CI: 1.18 to 4.28).
Discrimination. For the endpoint of cardiovascular death
or nonfatal congestive heart failure, the C-index of the
Predictors of Circulating hs-TnI and hs-TnTTable 2 Predictors of Circulating hs-TnI and hs-TnT
Determinant
Univariate A
hs-TnI: Standardized
Beta (p)
Treatment assignment at baseline 0.008 (0.637)
Age 0.169 (0.001)
Male sex 0.095 (0.001)
BMI 0.075 (0.001)
LVEF 50% 0.115 (0.001)
eGFR 0.109 (0.001)
Current smoking 0.030 (0.067)
Previous hypertension 0.119 (0.001)
Documented myocardial infarction 0.117 (0.001)
Diabetes mellitus 0.051 (0.002)
Intermittent claudication 0.054 (0.001)
TIA 0.014 (0.397)
Stroke 0.056 (0.001)
PCI 0.096 (0.001)
CABG 0.130 (0.001)
Total cholesterol 0.020 (0.240)
Use of beta-blockers 0.0002 (0.988)
Use of lipid-lowering drugs 0.077 (0.001)
Use of aspirin and antiplatelet medications 0.057 (0.001)
CRP 0.089 (0.001)
NT-proBNP 0.387 (0.001)
hs-TnT 0.442 (0.001)
hs-TnI
*Final models for logarithmically transformed hs-TnI and hs-TnT. Variables identified in univariate a
test. Multivariate models thus differ for hs-Tnl and hs-TnT. Determination coefficients (r2 values) f
BMI  body mass index; CABG  coronary artery bypass grafting; PCI  percutaneous coronarmultivariate model that included conventional risk markers,CRP, and NT-proBNP was 0.763 (95% CI: 0.725 to
0.801). Adding hs-TnI to the model resulted in a small but
significant increase in the C-index (Table 7). Similar results
were obtained for hs-TnT. For the endpoint of AMI, the
C-index of the multivariate model that included CRP and
NT-proBNP was 0.647 (95% CI: 0.597 to 0.696). Adding
hs-TnI to the model did not significantly increase the
C-index, nor did the addition of hs-TnT.
The integrated discrimination improvement values for
these endpoints were also calculated. Adding hs-TnI to the
models resulted in highly significant improvements in the
performance of the models for cardiovascular death or
nonfatal congestive heart failure (Table 7). Similar results
were obtained for hs-TnT. Adding hs-TnI or hs-TnT to
the models for AMI did not significantly improve the
performance of the models.
Interaction with trandolapril therapy. No significant in-
teraction was observed between concentration of hs-TnI or
hs-TnT and the effect of trandolapril on the endpoint of
cardiovascular death or heart failure. Moreover, trandolapril
therapy was not associated with a significantly reduced
incidence of the combined endpoint of cardiovascular death
or heart failure in the small subgroup of patients who were
in the fourth quartiles of both hs-TnI and hs-TnT (HR:
s Multivariate Analysis*
nT: Standardized
Beta (p)
hs-TnI: Standardized
Beta (p)
hs-TnT: Standardized
Beta (p)
0.029 (0.088)
0.325 (0.001) 0.041 (0.018) 0.239 (0.001)
0.176 (0.001) 0.164 (0.001) 0.248 (0.001)
0.044 (0.009) 0.017 (0.001) 0.096 (0.001)
0.079 (0.001) 0.025 (0.112)
0.155 (0.001) 0.025 (0.122) 0.053 (0.001)
0.120 (0.001) 0.044 (0.004)
0.106 (0.001) 0.084 (0.001) 0.062 (0.001)
0.005 (0.781) 0.087 (0.001)
0.121 (0.001) 0.034 (0.027) 0.113 (0.001)
0.057 (0.001)
0.025 (0.147)
0.066 (0.001)
0.103 (0.001) 0.036 (0.025) 0.043 (0.004)
0.134 (0.001) 0.033 (0.048)
0.057 (0.001)
0.027 (0.110)
0.058 (0.001)
0.074 (0.001)
0.046 (0.006) 0.027 (0.088)
0.298 (0.001) 0.374 (0.001) 0.234 (0.001)
0.442 (0.001)
s with p0.20 were entered into the multivariate model, which was further reduced by the F-ratio
els for hs-TnI and hs-TnT were 0.461 and 0.483, respectively.
ention; Other abbreviations and units as in Table 1.nalysi
hs-T






nalyse0.84; 95% CI: 0.59 to 1.21; p  0.35).
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The main finding of the present study is that small eleva-
tions in hs-TnI are associated with the incidence of cardio-
vascular death or heart failure in patients with stable CAD
and provide incremental prognostic information to conven-
tional risk markers and prognostic cardiovascular biomark-
ers, including hs-TnT. Interestingly, the correlation be-
tween hs-TnI and hs-TnT concentrations was of only
Figure 2 Risk for Cardiovascular Death or Heart Failure by Bas
Cumulative incidence of the composite endpoint of cardiovascular death or hospitaliza
(hs-TnI). There was a strong and graded association between increasing quartiles of c
Final Multivariate Cox Regression Modelsfor Cardiovascular Death o Congestive Heart FaTable 3 F nal Multivariate Cox Regression Mfor Cardiovascular Death or Conges
Variable
Fourth Quartile f
HR (95% CI)
hs-TnI 1.88 (1.33–2.66
hs-TnT 1.43 (1.01–2.04
Age 1.04 (1.02–1.07
LVEF 50% 1.24 (0.90–1.70
eGFR 1.00 (0.99–1.00
Current smoking 1.64 (1.10–2.45
History of hypertension 1.19 (0.87–1.63
History of myocardial infarction 1.11 (0.81–1.52
History of diabetes mellitus 1.74 (1.24–2.44
History of CABG 1.54 (1.13–2.10
Serum total cholesterol 1.00 (1.00–1.01
History of intermittent claudication 1.73 (1.18–2.53
Lipid-lowering therapy 0.70 (0.52–0.95
NT-proBNP 1.52 (1.28–1.80
CRP 1.04 (0.90–1.24*HRs based on a 1-SD change in the natural logarithm of troponin concentra
CI  confidence interval; HR  hazard ratio; Other abbreviations and unitsmoderate strength, suggesting that mechanisms of release
and/or degradation may potentially differ between the tro-
ponins in the chronic setting. Furthermore, hs-TnI, but not
hs-TnT, was significantly and independently associated
with both prior AMI and the incidence of subsequent AMI.
Determinants of hs-TnI and hs-TnT in patients with
stable CAD. Troponin I and T are components of the
contractile apparatus of cardiomyocytes, but small quantities
hs-TnI Level
r heart failure by baseline concentrations of high-sensitivity cardiac troponin I
troponin I and the risk for cardiovascular death or hospitalization for heart failure.
ls
eart Failure
nI and hs-TnT Continuous hs-TnI and hs-TnT
p Value HR (95% CI) p Value
0.0001 1.18 (1.01–1.36)* 0.033
0.045 1.51 (1.17–1.95)* 0.001
0.0001 1.04 (1.01–1.06) 0.001
0.19 1.22 (0.89–1.68) 0.220
0.37 1.00 (0.99–1.01) 0.423
0.016 1.60 (1.07–2.39) 0.022
0.27 1.22 (0.90–1.67) 0.201
0.53 1.09 (0.79–1.51) 0.586
0.001 1.71 (1.23–2.39) 0.002
0.007 1.45 (1.06–1.98) 0.019
0.085 1.00 (1.00–1.01) 0.041
0.005 1.61 (1.10–2.37) 0.015
0.024 0.70 (0.52–0.95) 0.024
0.0001 1.55 (1.31–1.84)* 0.0001
0.60 1.03 (0.89–1.21)* 0.671eline
tion fo
ardiacilureod
tive H
or hs-T
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)tion.
as in Tables 1 and 2.
ncentra
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March 26, 2013:1240–9 Troponin I in Stable CADof free troponin I and T are also believed to be present in the
cytoplasm as an early releasable pool (16). The troponin
subunits each play a unique functional role, and it is also
possible that different troponin fragments may have differ-
ential biological activity (16). Traditionally, cardiac tro-
ponins have been considered markers of myocardial necro-
sis, typically in the setting of acute coronary syndromes, but
recent observations that very low levels of both cTnT and
cTnI are found circulating in patients with stable CAD (4),
and even in the general population (17–19), has challenged
this paradigm. Alternative mechanisms for low-level tro-
ponin release have therefore been proposed, including car-
diomyocyte apoptosis and increased physiological cell turn-
over (20). These mechanisms could be relevant in the
setting of increased myocardial strain (21,22) and increased
LV mass and remodeling (17,23). In addition, a reversible
Final Multivariate Cox Regression Models for MTable 4 Final Multivariate Cox Regression M
Variable
Fourth Quartile for h
HR (95% CI)
hs-TnI 1.44 (1.03–2.01)
hs-TnT 0.93 (0.65–1.31)
Age 1.01 (0.99–1.03)
LVEF 50% 1.22 (0.89–1.66)
Current smoking 1.73 (1.22–2.46)
History of hypertension 1.19 (0.89–1.58)
History of diabetes mellitus 1.70 (1.21–2.37)
History of CABG 1.59 (1.17–2.17)
NT-proBNP 1.06 (0.90–1.25)
CRP 1.16 (1.01–1.34)
*HRs based on a 1-SD change in the natural logarithm of troponin co
Abbreviations and units as in Tables 1 to 3.
Final Multivariable Cox Regressions Models forCardiovascular D ath or Conge tive Heart FailureDichotomized t Sex-Specific 99th Percentile ofHe lthy Subjects
Table 5
Final Multivariable Cox Regressions Models for
Cardiovascular Death or Congestive Heart Failure
Dichotomized at Sex-Specific 99th Percentile of
Healthy Subjects
Variable
>99th Percentile for
hs-TnI and hs-TnT
HR (95% CI) p Value
hs-TnI 1.96 (1.40–2.74) 0.0001
hs-TnT 1.43 (1.00–2.05) 0.051
Age 1.04 (1.02–1.07) 0.0001
LVEF 50% 1.24 (0.90–1.70) 0.19
eGFR 1.00 (0.99–1.00) 0.36
Current smoking 1.62 (1.08–2.42) 0.019
History of hypertension 1.21 (0.89–1.65) 0.23
History of myocardial infarction 1.13 (0.82–1.55) 0.46
History of diabetes mellitus 1.75 (1.25–2.45) 0.001
History of CABG 1.55 (1.13–2.11) 0.006
Serum total cholesterol 1.00 (1.00–1.01) 0.089
History of intermittent claudication 1.72 (1.17–2.51) 0.005
Lipid-lowering therapy 0.69 (0.51–0.95) 0.020
NT-proBNP 1.52 (1.28–1.81) 0.0001
CRP 1.04 (0.90–1.20) 0.60Abbreviations and units as in Tables 1 to 3.increase in cell wall permeability to cardiac troponins or
troponin fragments after short periods of myocardial isch-
emia (24) would be compatible with the chronic, low-grade
elevations of cardiac troponins observed in patients with
stable CAD and in those with chronic heart failure.
Although cTnI and cTnT display very similar serum
profiles after acute ischemic injury and have been considered
to provide largely interchangeable diagnostic and prognostic
information in the setting of acute coronary syndromes (5),
the 2 have differing biological characteristics that may be
of clinical relevance in the ambulatory setting, where
chronic rather than acute injury is responsible for tro-
ponin release. Although we observed that hs-TnT and
hs-TnI shared several determinants, the strength of
associations differed somewhat for many of these factors.
For instance, the impact of prior AMI appeared to play a
more important role for circulating hs-TnI levels than for
hs-TnT levels. In contrast, the impact of renal function,
age, and sex appeared to be slightly stronger for hs-TnT
than for hs-TnI.
Several factors may contribute to these differences in
distribution patterns. First, the molecular size of troponin I
(24 kDa) is smaller than that of troponin T (37 kDa), which
may facilitate transfer of troponin I or troponin I fragments
across the viable cell membrane. Moreover, the degradation
mechanisms may differ (16). For instance, in patients with
renal failure, the association with LV mass may be stronger
for troponin T than for troponin I (25). We have previously
reported that cTnI may increase in proportion to the
severity of myocardial ischemia (8), whereas no such asso-
ciation was evident for cTnT in a similar study (7). These
differences suggest that although both hs-TnI and hs-
TnT are markers of subclinical cardiac injury, they may reflect
subtle differences in the etiology of cardiac injury and clearance
mechanisms from the circulation. As such, they may be
complementary rather than redundant biomarkers.
Prognostic value of hs-TnI and hs-TnT in patients with
stable CAD. The finding that hs-TnI and hs-TnT display
rdial Infarctionls for Myocardial Infarction
nd hs-TnT Continuous hs-TnI and hs-TnT
p Value HR (95% CI) p Value
0.031 1.21 (1.04–1.41)* 0.013
0.67 0.97 (0.84–1.13)* 0.714
0.25 1.01 (0.99–1.03) 0.262
0.21 1.21 (0.89–1.65) 0.232
0.002 1.71 (1.21–2.43) 0.003
0.24 1.19 (0.90–1.59) 0.227
0.002 1.70 (1.22–2.38) 0.002
0.003 1.55 (1.14–2.12) 0.006
0.46 1.05 (0.89–1.23) 0.580
0.039 1.16 (1.00–1.34) 0.043
tion.yocaode
s-TnI aslightly different patterns of distribution and determinants
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raises the questions of whether hs-TnI and hs-TnT may
have different diagnostic and prognostic properties. The
observation that hs-TnI is increased above the 99th percen-
tile in a lower percent of patients with stable CAD than
hs-TnT may have diagnostic implications; that is, the
signal-to-noise ratio may differ between the 2 with regard to
the detection of acute ischemic myocardial injury. More-
over, the finding that hs-TnI, but not hs-TnT, was inde-
pendently associated with the incidence of AMI may also
reflect biological differences that translate into different
prognostic properties. The exact mechanism underlying the
association between hs-TnI and the incidence of AMI
remains unknown. Recent computed tomographic angio-
graphic data demonstrating higher troponin levels in pa-
tients with remodeled, noncalcified plaques are compatible
with the idea that chronic but clinically silent rupture of
atherosclerotic plaques may cause microembolization that
may be a source of chronic troponin elevation (26). More-
over, as patients with remodeled, noncalcified plaques are
thought to be those at highest risk for future plaque rupture,
this may provide a rationale for the association between hs-TnI
and the risk for future AMI. However, it remains unclear why
such a mechanisms would preferentially involve hs-TnI, and
the finding requires confirmation in other study cohorts.
A strong association between chronic circulating concen-
trations of hs-TnT and the incidence of cardiovascular
death or congestive heart failure was first reported in
patients with stable CAD (4) and subsequently confirmed in
several large, population-based studies (17–19). Moreover,
the Heart Outcomes Prevention Evaluation investigators
recently reported an association between hs-TnI levels and
the risk for cardiovascular events in a high-risk population
(9). The present study extends this information by showing
that both hs-TnI and hs-TnT provide strong and indepen-
Risk Associated With Concordant or Discordant Levels of hs-TnI anTable 6 Risk Associated With Concordant or Discordant Levels
Variable n
hs-TnI low and hs-TnT low (reference category) 942
(hs-TnI high and hs-TnT low) or (hs-TnI low and hs-TnT high) 1,047
hs-TnI high and hs-TnT high 1,509
“High” defined as greater or equal to the sex-specific 75th percentile of healthy subjects (hs-TnI: 4
lower than the sex-specific 75th percentile of healthy subjects.
Abbreviations as in Tables 1 to 3.
C-Index and IDI: Effect of Adding hs-TnI and hs-TnT to MultivariateTable 7 C-Index and IDI: Effect of Adding hs-TnI and hs-TnT to
Variable
Dichotomous hs-TnI and hs-TnT
C-Index (95% CI) p Value IDI
Multivariate model without
hs-TnI or hs-TnT
0.763 (0.725–0.801) NA
hs-TnI 0.777 (0.740–0.814) 0.046 0.010 (0.007–0.
hs-TnT 0.774 (0.737–0.811) 0.048 0.006 (0.003–0.IDI  integrated discrimination improvement; NA  not applicable; Other abbreviations as in Tables 1 todent prognostic information for the endpoints of cardiovas-
cular death or congestive heart failure, underscoring that
chronic, low-grade injury may represent an intermediate phe-
notype in the pathway to congestive heart failure among at-risk
patients. Future studies must identify therapeutic strategies
that mitigate risk associated with these pathways.
Strengths and limitations. Strengths of the present inves-
tigation include the large sample size, long-term follow-up
period, and large number of endpoints. Moreover, the
prospective observational design of the PEACE biomarker
study and the inclusion of both hs-TnI and hs-TnT in the
same analysis represent strengths. A limitation of our study
is that we cannot rule the possibility that part of the
observed differences are due not to differing biological
characteristics of cTnI and cTnT but rather to analytical
differences between the assays. Along the same line of
argument, our results cannot be extrapolated to other
hs-TnI assays. It should also be noted that we used a
pre-commercial version of the hs-TnT assay and that the
results may deviate slightly from those obtained from the
current commercial version. However, the main finding of
our study, that hs-TnT and hs-TnI provide complementary
prognostic information, is unlikely to have been influenced
by the minor analytical differences between the pre-
commercial and current versions of the assay.
Conclusions
In patients with stable CAD and preserved LV systolic
function, concentrations of hs-TnI and hs-TnT are corre-
lated only moderately. hs-TnI concentrations are indepen-
dently associated with the risk for cardiovascular death or
heart failure and provide incremental prognostic informa-
tion to conventional risk markers and other cardiovascular
biomarkers, including hs-TnT. Notably, hs-TnI, but not
TnTs-TnI and hs-TnT
Cardiovascular Death or
Heart Failure Myocardial Infarction
HR (95% CI) p Value HR (95% CI) p Value
5 (1.18–4.28) 0.014 0.96 (0.66–1.39) 0.819
7 (4.30–13.35) 0.001 1.10 (0.79–1.55) 0.572
l in men, 2.8 pg/ml in women; hs-TnT: 5.6 pg/ml in men, 3.9 pg/ml in women). “Low” defined as
ls for Cardiovascular Death or Heart Failurevariate Models for Cardiovascular Death or Heart Failure
Continuous hs-TnI and hs-TnT
p Value C-Index (95% CI) p Value IDI p Value
0.763 (0.725–0.801) NA
0.001 0.778 (0.741–0.814) 0.026 0.008 (0.005–0.012) 0.001
0.001 0.785 (0.749–0.821) 0.004 0.011 (0.007–0.014) 0.001d hs-of h
2.2
7.5
.2 pg/mModeulti
014)
009)3.
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March 26, 2013:1240–9 Troponin I in Stable CADhs-TnT, was significantly associated with the risk for AMI.
Accordingly, chronic, low-grade elevation of hs-TnI and
hs-TnT in patients with stable CAD may potentially reflect
different pathophysiological determinants and suggest dif-
ferent therapeutic responses.
Reprint requests and correspondence: Professor Torbjørn Om-
land, Akershus University Hospital, Division of Medicine, NO-
1478 Lørenskog, Norway. E-mail: torbjorn.omland@
medisin.uio.no.
REFERENCES
1. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/
ACCF/AHA/WHF Task Force for the Redefinition of Myocardial
Infarction. Universal definition of myocardial infarction. J Am Coll
Cardiol 2007;50:2173–95.
2. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA
focused update incorporated into the ACC/AHA 2007 guidelines for
the management of patients with unstable angina/non-ST-elevation
myocardial infarction: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2011;57:e215–367.
3. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac
troponin I and T assay 99th percentile values from a common
presumably healthy population. Clin Chem 2012;58:1574–81.
4. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac
troponin T assay in stable coronary artery disease. N Engl J Med
2009;361:2538–47.
5. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of
cardiac troponin measurement in acute cardiac care. Eur Heart J
2010;31:2197–204.
6. Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute
myocardial infarction in patients with pre-existing coronary artery
disease using more sensitive cardiac troponin assays. Eur Heart J
2012;33:988–97.
7. Røysland R, Kravdal G, Høiseth AD, et al. Cardiac troponin T levels
and exercise stress testing in patients with suspected coronary artery
disease: the Akershus Cardiac Examination (ACE) 1 study. Clin Sci
(Lond) 2012;122:599–606.
8. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E.
Detection of acute changes in circulating troponin in the setting of
transient stress test-induced myocardial ischaemia using an ultrasen-
sitive assay: results from TIMI 35. Eur Heart J 2009;30:162–9.
9. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac
troponin I measurement for risk stratification in a stable high-risk
population. Clin Chem 2011;57:1146–53.
10. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-
converting-enzyme inhibition in stable coronary artery disease. N Engl
J Med 2004;351:2058–68.
11. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of
B-Type natriuretic peptides in patients with stable coronary artery
disease: the PEACE trial. J Am Coll Cardiol 2007;50:205–14.12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the
Modification of Diet in Renal Disease Study Group. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Ann Intern Med 1999;130:461–70.
13. Shtatland E, Kleinman K, Cain EM. Model building in PROC
PHREG with automatic variable selection and information criteria.
Available at: http://www2.sas.com/proceedings/sugi30/206-30.pdf.
Accessed January 15, 2013.
14. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination
in survival analysis: model specific population value and confidence
interval estimation. Stat Med 2004;23:2109–23.
15. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72.
16. McDonough JL, Van Eyk JE. Developing the next generation of
cardiac markers: disease-induced modifications of troponin I. Prog
Cardiovasc Dis 2004;47:207–16.
17. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin
T detected with a highly sensitive assay and cardiac structure and
mortality risk in the general population. JAMA 2010;304:2503–12.
18. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of
serial measures of cardiac troponin T using a sensitive assay with
incident heart failure and cardiovascular mortality in older adults.
JAMA 2010;304:2494–502.
19. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T
measured by a highly sensitive assay predicts coronary heart disease,
heart failure, and mortality in the Atherosclerosis Risk in Communi-
ties Study. Circulation 2011;123:1367–76.
20. White HD. Pathobiology of troponin elevations: do elevations occur
with myocardial ischemia as well as necrosis? J Am Coll Cardiol
2011;57:2406–8.
21. Hessel MH, Atsma DE, van der Valk EJ, et al. Release of cardiac
troponin I from viable cardiomyocytes is mediated by integrin stimu-
lation. Pflugers Arch 2008;455:979–86.
22. Feng J, Schaus BJ, Fallavollita JA, et al. Preload induces troponin I
degradation independently of myocardial ischemia. Circulation 2001;
103:2035–7.
23. Røsjø H, Andreassen J, Edvardsen T, Omland T. Prognostic useful-
ness of circulating high-sensitivity troponin T in aortic stenosis and
relation to echocardiographic indexes of cardiac function and anatomy.
Am J Cardiol 2011;108:88–91.
24. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive
troponin I and T modification detected in serum from patients with
acute myocardial infarction. Circulation 2000;102:1221–6.
25. Petrovic D, Obrenovic R, Stojimirovic B. Cardiac troponins and left
ventricular hypertrophy in hemodialysis patients. Clin Lab 2008;54:
145–52.
26. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin
release in patients with stable coronary artery disease: insights from CT
angiography characteristics of atherosclerotic plaque. Heart 2011;97:
823–31.Key Words: cardiovascular death y coronary artery disease y natriuretic
peptides y troponin.
